Related Experiment Video
Updated: May 5, 2026
A Flow Cytometry-based Assay for Measuring Mitochondrial Membrane Potential in Cardiac Myocytes After Hypoxia/Reoxygenation
Published on: July 13, 2018
Peptide PDRPS6 attenuates myocardial ischemia injury by improving mitochondrial function
Mengwen Feng1, Li Zhang2, Anwen Yin3
1Hongqiao International Institute of Medicine, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xianxia Road, Shanghai, 200336, China; Department of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, 221004, China.
A novel peptide, PDRPS6, effectively treats myocardial ischemia-reperfusion injury by improving mitochondrial function and reducing cell death. This peptide offers a promising new therapeutic approach for heart conditions.
Area of Science:
- Cardiovascular Research
- Mitochondrial Biology
- Cellular Injury Mechanisms
Background:
- Mitochondrial dynamics are critical in myocardial ischemia-reperfusion (I/R) injury, but effective regulators are lacking.
- An imbalance between mitochondrial fusion and fission contributes to I/R injury.
- The peptide derived from 40 S ribosomal protein S6 (PDRPS6) is linked to hypoxic stress.
Purpose of the Study:
- To investigate the protective function and mechanism of PDRPS6 in myocardial I/R injury.
- To determine if PDRPS6 can ameliorate cardiac damage and dysfunction caused by I/R.
- To elucidate the molecular pathways through which PDRPS6 exerts its effects.
Main Methods:
- In vivo studies using a rat model of myocardial I/R injury.
- In vitro assessment of cardiomyocyte apoptosis and mitochondrial function.
- Analysis of reactive oxygen species (ROS) levels and mitochondrial membrane potential (MMP).
- Pull-down assays to identify PDRPS6 interacting proteins, including PGAM5 and Drp1.
Main Results:
- PDRPS6 administration reduced myocardial tissue injury, cardiomyocyte apoptosis, and improved cardiac function in vivo.
- PDRPS6 significantly decreased apoptosis in vitro and protected mitochondrial function.
- PDRPS6 lowered ROS levels, maintained MMP, and inhibited mitochondrial fission.
- PDRPS6 targets PGAM5, leading to dephosphorylation of Drp1 at ser616, which was partially reversed by PGAM5 overexpression.
Conclusions:
- PDRPS6 demonstrates significant cardioprotective effects against I/R injury.
- PDRPS6 functions by enhancing mitochondrial integrity and reducing oxidative stress.
- PDRPS6 represents a novel therapeutic strategy for myocardial I/R injury via the PGAM5/Drp1 pathway.
